Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis

Abstract

This meta-analysis aimed to comprehensively assess the efficacy and safety of hepatic resection combined with radiofrequency ablation versus hepatic resection (HR) alone for the treatment of multifocal hepatocellular carcinomas (HCC). A literature search was conducted from the database including MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and China Biology Medicine (CBM) disc. The primary outcomes included the 1-, 3-, 5-year overall survival (OS) and disease-free survival (DFS) rate. The secondary outcomes contained the intraoperative parameters and postoperative adverse events (AEs). These parameters were all analyzed by RevMan 5.3 software. After carefully screening relevant studies, four retrospective studies of high quality involving 466 patients (197 in the combined group and 269 in the HR group) were included in this study. The pooled results showed that the 1-, 3-, 5-year OS rate in the combined group were comparable with those in the HR group (OR=0.77, 0.96, 0.88; P=0.33, 0.88, 0.70, respectively). Similarly, there was no significant difference in 1-, 3-, 5-year DFS rate between the combined group and the HR alone group (OR=0.57, 0.83, 0.72; P=0.17, 0.37, 0.32, respectively). And the intraoperative parameters and postoperative AEs were also comparable between the above two cohorts. However, two included studies reported that tumor often recurred in the ablation site in the combined group. The present meta-analysis indicated that the HR combined with RFA could reach a long-term survival outcome similar to curative HR for multifocal HCC patients. And this therapy may be a promising alternative for these patients with marginal liver function or complicated tumor distribution. Furthermore, high quality randomized controlled trials (RCTs) are imperative to verify this conclusion.

Keywords

hepatic resection / radiofrequency ablation / multifocal hepatocellular carcinoma / long-term survival outcome

References

[1] LiuJ, FanD. Hepatitis B in China. Lancet, 2007, 369(9573): 1582-1583 PMID: 17499584

[2] LlovetJM, Zucman-RossiJ, PikarskyE, et al. . Hepatocellular carcinoma. Nat Rev Dis Primers, 2016, 2: 16018 PMID: 27158749

[3] OmerRE, KuijstenA, KadaruAM, et al. . Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr Cancer, 2004, 48(1): 15-21 PMID: 15203373

[4] National Center for Health S.. Health, United States. Health, United States, 2014: With Special Feature on Adults Aged 55–64, 2015, Hyattsville (MD), National Center for Health Statistics (US)

[5] MazzantiR, GramantieriL, BolondiL. Hepatocellular carcinoma:epidemiology and clinical aspects. Mol Aspects Med, 2008, 29(1-2): 130-143 PMID: 18061252

[6] de LopeCR, TremosiniS, FornerA, et al. . Management of HCC. J Hepatol, 2012, 56: S75-S87 PMID: 22300468

[7] YiPS, ZhangM, XuMQ. Management of the middle hepatic vein in right lobe living donor liver transplantation: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(4): 600-605 PMID: 26223934

[8] BruixJ, ShermanM. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53(3): 1020-1022 PMID: 21374666 PMCID: 3084991

[9] EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.. Eur J Cancer, 2012, 48(5): 599-641

[10] BruixJ, LlovetJM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 2002, 35(3): 519-524 PMID: 11870363

[11] LlovetJM, RealMI, MontanaX, et al. . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-1739 PMID: 12049862

[12] LlovetJM, RicciS, MazzaferroV, et al. . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390 PMID: 18650514

[13] XuQ, KobayashiS, YeX, et al. . Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients. Sci Rep, 2014, 4: 7252 PMID: 25429732 PMCID: 4246212

[14] XuG, QiFZ, ZhangJH, et al. . Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma. World J Surg Oncol, 2012, 10: 163 PMID: 22897815 PMCID: 3491005

[15] WangJH, WangCC, HungCH, et al. . Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol, 2012, 56(2): 412-418 PMID: 21756858

[16] TakayamaT, MakuuchiM, HasegawaK. Single HCC smaller than 2 cm: surgery or ablation?: surgeon's perspective. J Hepatobiliary Pancreat Sci, 2010, 17(4): 422-424 PMID: 19936598

[17] ChoiD, LimHK, JohJW, et al. . Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol, 2007, 14(12): 3510-3518 PMID: 17653800

[18] PoonRT. Radiofrequency ablation combined with resection enhances chance for curative treatment of hepatocellular carcinoma. Ann Surg Oncol, 2007, 14(12): 3299-3300 PMID: 17899286 PMCID: 2077909

[19] PawlikTM, IzzoF, CohenDS, et al. . Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol, 2003, 10(9): 1059-1069 PMID: 14597445

[20] CheungTT. Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: Prognosis and outcomes. World J Gastroenterol, 2010, 16(24): 3056 PMID: 20572310 PMCID: 2890947

[21] YanJ, LiX, XIAF. Survival analysis of radio frequency ablation combined with liver resection for dual lobe multifocal hepatocellular carcinoma. Abdom Surg, 2012, 25(2): 76-78

[22] LeeSJ, ChoEH, KimR, et al. . Hepatectomy, combined with intraoperative radiofrequency ablation in patients with multiple hepatocellular carcinomas. Korean J Hepatobiliary Pancreat Surg, 2015, 19(3): 98-102 PMID: 26379730 PMCID: 4568598

[23] ZhangT, ZengY, HuangJ, et al. . Combined resection with radiofrequency ablation for bilobar hepatocellular carcinoma: a single-center experience. J Surg Res, 2014, 191(2): 370-378 PMID: 24766727

[24] HigginsJPT, SterneJAC. HigginsJPT, GreenS. Chapter 8: Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions (version 5.1.0), 2011, Chichester, John Wiley & Sons, Ltd, 1-53

[25] StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605 PMID: 20652370

[26] HozoSP, DjulbegovicB, HozoI. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005, 5: 13 PMID: 15840177 PMCID: 1097734

[27] HsuCY, HsiaCY, HuangYH, et al. . Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol, 2012, 19(3): 842-849 PMID: 21913008

[28] YinL, LiH, LiAJ, et al. . Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol, 2014, 61(1): 82-88 PMID: 24650695

[29] HouYF, WeiYG, YangJY, et al. . Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary Pancreat Diseas Internat, 2016, 15(4): 378-385